Deposition of amyloid proteins in the epicardial coronary arteries of 58 patients with primary systemic amyloidosis

Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Cardiovascular Pathology (Impact Factor: 2). 03/2007; 16(2):75-8. DOI: 10.1016/j.carpath.2006.09.011
Source: PubMed


We sought to determine the distribution and the effect of amyloid on epicardial coronary arteries in patients with primary cardiac amyloidosis.
We reviewed pathologic specimens taken after autopsy or cardiac transplantation from 58 patients with primary cardiac amyloidosis. Patients were seen from 1981 to 2000. Multiple sections of epicardial coronary arteries (left anterior descending artery, left circumflex artery, and right coronary artery) were examined to determine the degree of amyloid deposition in the intima, media, adventitia, and vasa vasorum (vasa vasorum are nutrient arteries for the coronary arteries themselves).
In 56 of 58 patients (97%), amyloid was present in epicardial coronary arteries. Amyloid was identified in all artery layers (intima, media, and adventitia), and more patients had amyloid in the adventitia. However, amyloid did not cause intraluminal obstruction of epicardial coronary arteries in any patient. The vasa vasorum had considerable deposits and, in many patients, were obstructed by amyloid. Patients with obstruction of the vasa vasorum were significantly more likely to have obstructive intramural coronary amyloidosis than patients without vasa vasorum obstruction (P=.002).
The epicardial coronary arteries of patients with primary cardiac amyloidosis had extensive amyloid deposition. This deposition, however, did not lead to obstruction of epicardial coronary arteries and therefore did not contribute to ischemic syndromes observed in these patients. Obstruction of the vasa vasorum was associated with obstructive intramural coronary amyloidosis.

Download full-text


Available from: William D Edwards, Jul 06, 2015
  • Source
    • "This is also supported by the fact that the percent reduction of involved LC from baseline was not predictive of overall survival , while the achievement of absolute low levels was[90]. OR criteria are defined for the 4 major relevant organs (heart, kidney, liver, nervous system)[59]and have been updated for heart[89]and kidney involvement[91]. The details on each OR can be viewed in table 2. The deeper the HR the higher the likelihood of achieving an OR[53,78,90919293. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunoglobulin amyloid light-chain (AL) amyloidosis is the most common form of systemic amyloidosis, where the culprit amyloidogenic protein is immunoglobulin light chains produced by marrow clonal plasma cells. AL amyloidosis is an infrequent disease, and since presentation is variable and often nonspecific, diagnosis is often delayed. This results in cumulative organ damage and has a negative prognostic effect. AL amyloidosis can also be challenging on the diagnostic level, especially when demonstration of Congo red-positive tissue is not readily obtained. Since as many as 31 known amyloidogenic proteins have been identified to date, determination of the amyloid type is required. While several typing methods are available, mass spectrometry has become the gold standard for amyloid typing. Upon confirming the diagnosis of amyloidosis, a pursuit for organ involvement is essential, with a focus on heart involvement, even in the absence of suggestive symptoms for involvement, as this has both prognostic and treatment implications. Details regarding initial treatment options, including stem cell transplantation, are provided in this review. AL amyloidosis management requires a multidisciplinary approach with careful patient monitoring, as organ impairment has a major effect on morbidity and treatment tolerability until a response to treatment is achieved and recovery emerges.
    Full-text · Article · Jan 2016 · Acta Haematologica
  • Source
    • "Autopsy studies reveal that the presence of amyloid in the perivascular and interstitial space is associated with histologic evidence of myocardial ischemia in 74% of patients [16]. Epicardial coronary perivascular infiltration is seen in 97% of coronaries that are predominantly but not exclusively non-obstructive [17]; patients present with angina, have impaired myocardial flow reserve and elevated troponin, indicating myocyte necrosis [4,18-21]. In colon specimens, markers of oxidative tissue stress such as lipid peroxidation products (hydroxynonenal and thiobarbituric acid reactive substances) and protein carbonyls were present surrounding amyloid deposits [22]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Light chain amyloidosis (AL) is a rare plasma cell dyscrasia associated with poor survival especially in the setting of heart failure. Late gadolinium enhancement (LGE) on cardiac MRI was recently found to correlate with myocardial amyloid deposition but the prognostic role is not established. The aim is to determine the prognostic significance of LGE in AL by comparing long term survival of AL patients with and without LGE. Twenty nine consecutive patients (14 females; 62 +/- 11 years) with biopsy-proven AL undergoing cardiac MRI with gadolinium as part of AL workup were included. Survival was prospectively followed 29 months (median) following MRI and compared between those with and without LGE by Kaplan-Meier and log-rank analyses. LGE was positive in 23 subjects (79%) and negative in 6 (21%). Left ventricular ejection fraction was 66 +/- 17% in LGE-positive and 69 +/- 12% in LGE-negative patients (p = 0.8). Overall 1-year mortality was 36%. On follow-up, 14/23 LGE-positive and none of LGE-negative patients died (log rank p = 0.0061). Presenting New York Heart Association heart failure class was also associated with poor survival (p = 0.0059). Survival between two LGE groups stratified by heart failure class still showed a significant difference by a stratified log-rank test (p = 0.04). Late gadolinium enhancement is common and is associated with poor long-term survival in light chain amyloidosis, even after adjustment for heart failure class presentation. The prognostic significance of late gadolinium enhancement in this disease may be useful in patient risk-stratification.
    Full-text · Article · Jun 2009 · BMC Medical Physics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac involvement occurs frequently in primary amyloidosis and is associated with heart failure hospitalizations and poor survival. The initial presentation of the disease may be misleading, resulting in under-diagnosis of cardiac amyloidosis and late initiation of treatment. We present a case of cardiac amyloidosis initially misdiagnosed as hypertrophic cardiomyopathy and we discuss the key findings of the disease along with the latest evidence regarding the management and prognosis of cardiac amyloidosis.
    Full-text · Article · Nov 2010 · Hellenic journal of cardiology: HJC = Hellēnikē kardiologikē epitheōrēsē
Show more